ELOS Syneron Medical Ltd. - Ordinary Shares

Aesthetic products company Syneron Medical (ELOS) has commenced the global launch of its new facial rejuvenation device. The device dubbed “eTwo,” which integrates advanced technologies for facial treatments, was recently featured in the annual congress of European Academy of Dermatology and Venereology (“EADV 2011”) in Lisbon, Portugal.

The eTwo is approved in the U.S. and Europe for dermatological procedures requiring ablation, resurfacing and wrinkle treatment. The device combines Syneron’s “Sublime” controlled heating and “Sublative” fractional skin treatment technologies.

Sublime utilizes safe and effective combination of infrared light and bipolar radio frequency energies to remodel the deep dermal layer of the skin by stimulating new collagen (a naturally occurring protein which keeps skin healthy) growth. The company’s Sublative fractionated bipolar radio frequency technology offers high dermal impact with low epidermal disruption.

Sublative places heat energy in the upper dermal layer, enabling significant enhancement in collagen and elastin (a complimentary protein to collagen) production for a brighter and smoother complexion. The twin technology has allowed Syneron to further advance skin rejuvenation treatments.

Syneron offers a comprehensive product portfolio and a global distribution setup. Its knowledge allows medical practitioners to provide sophisticated solutions for a wide range such as wrinkle reduction, hair removal and body contouring. The company faces some competition from Cutera (CUTR) among others.

Syneron’s product line-up includes items for skincare for both the home-use and professional segments. The company markets and supports its products in about 86 nations.

Syneron’s revenues for second-quarter fiscal 2011 soared 24% year over year, fueled by strong sales from its Emerging Business Units (“EBU”) segment. Revenues from the EBU unit more than doubled on a sequential basis, in part, boosted by higher sales of the elure advanced skin lightening products. Syneron is scheduled to report its third quarter results on November 10.

Syneron Medical Ltd. - Ordinary Shares (NASDAQ:ELOS)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024

Syneron Medical Ltd. - Ordinary Shares (NASDAQ:ELOS)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024